Natera, Inc. ($NTRA) Stock Forecast: Down 5.3% Today

What is Natera, Inc.?

Natera Inc. (NTRA) is a medical diagnostics and research company specializing in genetic testing platforms in women's health, oncology, and organ health. Despite facing concerns over insider selling, the company has shown strong growth potential and positive analyst sentiment.

Why is Natera, Inc. going down?

NTRA stock is down 5.3% on Jun 2, 2026 18:01

• The bearish movement in NTRA today could be attributed to the significant insider selling totaling $56.0 million in the last three months, raising concerns among investors about the company's future prospects.
• Despite an optimistic "Outperform" rating and a price target of $260.00, the overvaluation of Natera by 9.2% according to GF Value™ might have contributed to the downward pressure on the stock.
• The rejection of an appeal in the false-advertising dispute with Natera by the U.S. Supreme Court could have added uncertainty and legal risks to Natera's operations, impacting investor confidence in the stock.
• While Natera has announced positive developments such as enhanced prenatal testing and market expansion, the ongoing insider selling and legal disputes might have overshadowed these advancements, leading to the bearish market movement today.

NTRA Price Chart

NTRA Technical Analysis

NTRA News

NTRA Assumed by Wolfe Research -- Rating Upgraded to Outperform

Wolfe Research has upgraded Natera (NTRA) to an "Outperform" rating with a price target of $260.00, reflecting a positive outlook despite the stock being 9.2% overvalued according to GuruFocus's GF Value™. Natera, a medical diagnostics and research company, shows strong growth potential (GF Score™ of 82/100, Growth 10/10) but faces concerns due to significant insider selling totaling $56.0 million in the last three months. Investors are advised to consider both the optimistic analyst rating and the insider activity with caution.

https://www.gurufocus.com/news/8896023/ntra-assumed-by-wolfe-research-rating-upgraded-to-outperform

Natera Inc stock (US6323071042): Wolfe Research initiation and recent price action in focus

Natera Inc. (NTRA) shares are gaining attention after Wolfe Research initiated coverage with an "outperform" rating and a $260 price target. The genetic testing specialist closed recently around $223 and has seen active trading, reflecting continued investor interest and positive analyst sentiment. The company's focus on expanding its genetic testing platforms in women's health, oncology, and organ health, alongside positive revenue growth, positions it as a key player in the US healthcare and diagnostics sector.

https://www.ad-hoc-news.de/boerse/news/ueberblick/natera-inc-stock-us6323071042-wolfe-research-initiation-and-recent/69467680

U.S. Supreme Court rejects CareDx appeal in Natera false-advertising dispute

The U.S. Supreme Court has rejected an appeal from CareDx in its false-advertising dispute with Natera. This decision marks a significant development in the ongoing legal battle between the two companies regarding their advertising practices. The article is a brief report from Refinitiv detailing this court ruling.

https://www.tradingview.com/news/reuters.com,2026:newsml_L6N42916H:0-u-s-supreme-court-rejects-caredx-appeal-in-natera-false-advertising-dispute/

Wolfe Research initiates Natera stock coverage with outperform rating By Investing.com

Wolfe Research has initiated coverage on Natera Inc. (NASDAQ:NTRA) with an outperform rating and a price target of $260, suggesting a 19% upside from its current trading price. The firm's valuation is based on Natera's market leadership in molecular residual disease testing, projected market expansion, and strong revenue growth, with assumptions about continued growth in prenatal and other testing offerings. Despite an InvestingPro analysis suggesting overvaluation, Natera has also announced several recent developments, including enhanced prenatal testing, expansion of its headquarters, increased clinical trial enrollment, and new collaborations.

https://ca.investing.com/news/stock-market-news/wolfe-research-initiates-natera-stock-coverage-with-outperform-rating-93CH-4669988

NTRA (NASDAQ: NTRA) insider sells multiple lots, files to resell 3,000 shares

An insider at Natera, Inc. (NTRA) has filed a Form 144, indicating an intention to resell 3,000 performance shares dated January 14, 2026. The filing also details multiple past sales by Solomon Moshkevich, including transactions on May 1, 2026, for 3,000 shares realizing $610,065.00, and on May 26, 2026, for 1,652 shares realizing $335,091.35. These sales represent significant insider activity at the company.

https://www.stocktitan.net/sec-filings/NTRA/144-natera-inc-sec-filing-c1ce622708dd.html

Trending Today

Bitcoin ($BTC) Crypto Forecast: Down 6.3% Today

Cardano ($ADA) Crypto Forecast: Down 7.6% Today

QTUM ($QTUM) Crypto Forecast: Down 6.4% Today

Ethereum ($ETH) Crypto Forecast: Down 7.1% Today

Tractor Supply Company ($TSCO) Stock Forecast: Down 5.4% Today

Monolithic Power Systems Inc. ($MPWR) Stock Forecast: Up 5.2% Today

Analog Devices Inc. ($ADI) Stock Forecast: Up 5.3% Today

Blink Charging Co. ($BLNK) Stock Forecast: Down 5.0% Today

ON Semiconductor Corporation ($ON) Stock Forecast: Up 6.4% Today

Shopify Inc. Class A Subordinate ($SHOP) Stock Forecast: Down 5.9% Today

Natera, Inc. Price History

08.04.2026 - NTRA Stock was down 7.7%

• Despite strong revenue growth driven by successful products like Fetal Focus and Signatera MRD test, Natera faced a bearish movement in its stock, potentially linked to a wider net loss reported in the same quarter, raising concerns about profitability.
• The missed EPS estimate and increased operating expenses leading to a higher net loss are likely factors contributing to the negative market sentiment towards Natera.
• Investors may be concentrating on the company's ability to manage expenses and bottom line performance, somewhat overshadowing the positive revenue growth and raised revenue guidance for the full year.
• The market's response could also be influenced by the stock's recent underperformance compared to the broader market, despite surpassing revenue expectations, suggesting a possible mismatch in investor expectations and market valuation.

15.04.2026 - NTRA Stock was down 5.3%

• Natera's stock experienced a strong bearish movement of 5.9% today.
• The market reacted negatively to Natera's Q1 2026 earnings report despite raising its 2026 revenue and gross margin guidance. This can be attributed to the wider net loss of US$85.09 million due to increased operating expenses for clinical trials, new products, and international expansion.
• Cathie Wood's ARK Invest's strategic shift towards increasing its stake in Natera while selling shares in other biotech companies may have also influenced market sentiment, signaling a shift in focus within the biotech sector.
• Analysts' mixed reactions to Natera's first-quarter results, with revenue beating expectations but statutory losses being larger than forecast, could have added to the overall bearish sentiment surrounding the stock.

20.04.2026 - NTRA Stock was up 5.1%

• The FDA's approval of Natera's Signatera CDx blood test as a companion diagnostic for muscle-invasive bladder cancer has led to a surge in the company's stock performance.
• This approval underscores the importance of MRD testing as a critical tool in clinical decision-making, potentially boosting revenue projections for Natera.
• Despite these positive developments, investors are advised to be wary of Natera's high expenditures, ongoing financial losses, as well as legal and regulatory challenges that could affect its future growth prospects.
• Despite recent declines in the stock price, Natera's robust revenue growth and optimistic analyst outlook suggest that the company may be undervalued, offering investors an opportunity to consider a bullish stance on Natera for the long term.

29.04.2026 - NTRA Stock was up 7.1%

• The bullish movement in Natera's stock could be attributed to the positive market reception of its collaboration with Diakonos Oncology Corp. for a Phase I/II trial in refractory melanoma using the Signatera test. This partnership aims to provide early insights into treatment response dynamics, which is a significant development in the field of personalized medicine.
• The recent sale of shares by the company's executives to cover tax obligations may have initially caused some uncertainty among investors. However, the market seems to have focused more on the promising collaboration and the potential impact on cancer treatment.
• Natera's announcement of an enhanced Panorama non-invasive prenatal test (NIPT) could also have contributed to the positive sentiment, showcasing the company's continued efforts in advancing its genetic testing portfolio and addressing medical needs across different areas.
• Overall, the market's bullish reaction to Natera's strategic collaborations and product enhancements reflects investor confidence in the company's growth prospects and its commitment to driving innovation in genetic testing and personalized medicine.

23.03.2026 - NTRA Stock was down 5.2%

• The recent bearish movement in Natera's stock could be attributed to:
• Profit-taking by insiders: Co-founder Sheena Jonathan and family trusts selling a significant number of shares could have indicated a lack of confidence in the short-term performance of the stock.
• Overvaluation concerns: Despite the recent price surge, valuation metrics like the Price-to-Sales (P/S) ratio suggesting overvaluation might have led investors to capitalize on their gains.
• Market dynamics: While Natera's stock experienced a downward trend, other companies in the healthcare sector, such as UFP Technologies, Mettler-Toledo, and Viatris, saw substantial gains, potentially diverting investor attention away from Natera.
• Overall market sentiment: The reopening of the Strait of Hormuz resulting in decreased logistics and energy costs may have redirected investor focus to companies directly benefiting from these changes, impacting Natera's stock negatively.

06.04.2026 - NTRA Stock was up 5.1%

• The bullish movement in Natera's stock today is linked to positive developments such as an "Outperform" rating from William Blair, a patent victory, and promising study results for its Signatera assay.
• The selling of shares by key executives like Sheena Jonathan, John Fesko, and CEO Steven Chapman to cover tax obligations initially raised concerns. However, these pre-arranged transactions, in light of positive news, likely reassured investors about the company's health and future prospects.
• Strategic selling of shares by company insiders under Rule 10b5-1 plans, despite the stock being down year-to-date, may indicate a prudent approach to finance management while maintaining confidence in company performance.
• The combination of positive company developments and strategic insider selling likely fueled the bullish movement in Natera's stock today, demonstrating a blend of financial responsibility and investor confidence in the company's growth trajectory.

30.03.2026 - NTRA Stock was up 5.1%

• The company revealed its first-quarter financial results and held a conference call, potentially boosting investor confidence and fueling the bullish movement.
• Insider selling by the co-founder and CEO, aimed at covering tax obligations, initially raised concerns but a clarified context of these sales being part of a pre-arranged trading plan may have alleviated any negative impact.
• Despite Natera's current lack of profitability, positive court rulings and new analyst coverage could have positively influenced investor sentiment, contributing to the bullish market performance.
• Taken together, positive updates on financial results, structured insider trading activities, and external factors like court decisions and analyst coverage likely played a role in Natera's recent strong bullish trend.

28.04.2026 - NTRA Stock was up 5.1%

• Today's bullish movement in Natera's stock is likely linked to positive updates on its clinical trials and innovations in genetic testing technologies.
• Commencement of patient enrollment for early-stage breast cancer studies and progress in trials for breast cancer and bladder cancer treatments have contributed to increased investor confidence.
• Upgrades to the Panorama prenatal test and FDA approval for Signatera in bladder cancer demonstrate Natera's dedication to innovation and expanding its market reach.
• Despite concerns regarding insider selling and valuation risks, the favorable outcomes in Natera's clinical trials and testing capabilities appear to have had a stronger impact, resulting in an upsurge in the stock price.

02.05.2026 - NTRA Stock was down 5.3%

• The bearish movement in NTRA today could be attributed to the significant insider selling totaling $56.0 million in the last three months, raising concerns among investors about the company's future prospects.
• Despite an optimistic "Outperform" rating and a price target of $260.00, the overvaluation of Natera by 9.2% according to GF Value™ might have contributed to the downward pressure on the stock.
• The rejection of an appeal in the false-advertising dispute with Natera by the U.S. Supreme Court could have added uncertainty and legal risks to Natera's operations, impacting investor confidence in the stock.
• While Natera has announced positive developments such as enhanced prenatal testing and market expansion, the ongoing insider selling and legal disputes might have overshadowed these advancements, leading to the bearish market movement today.

29.03.2026 - NTRA Stock was down 5.0%

• The downward trend in Natera's stock price could be linked to notable insider selling activity by directors such as Roelof Botha, Eric H. Rubin, and Ruth Williams Brinkley. This activity may have sparked concerns among investors regarding the company's future outlook.
• Despite the release of positive information regarding Natera's recent clinical evidence for its Prospera transplant test, which could potentially boost revenue, the overall market sentiment may have been clouded by the insider selling, as well as the company's negative net margins and ROE.
• While the initial increase in M&T Bank Corp's stake could have been viewed as a positive development, investor focus appeared to shift towards the insider selling and the company's financial difficulties, contributing to today's bearish movement in the stock.

08.04.2026 - NTRA Stock was down 6.0%

• Natera's strong revenue growth and milestone of processing over 1 million tests in a quarter showcased its continued expansion and market demand for its services.
• The wider loss per share than expected could have contributed to the bearish movement in the stock, despite positive revenue performance.
• The sale of shares by the Executive Chairman to cover tax obligations may have also impacted investor sentiment, leading to a decline in the stock price.
• Overall, while Natera's operational performance remains robust, market reaction to the earnings miss and insider selling likely drove the bearish movement in the stock today.

11.04.2026 - NTRA Stock was up 5.1%

• Despite concerns over its high valuation influencing a decline in stock price, Natera's impressive Q1 earnings call, demonstrating revenue growth and increased volume, has boosted investor confidence.
• Analysts have raised the 12-month price target to $260.78, indicating a 19% potential upside, reflecting optimism regarding Natera's future performance.
• The unexpected Q4 profit of US$47.3 million has shifted focus from prior losses to potential growth, although discussions on the stock's valuation persist among investors.
• Analysts' continued Buy rating and optimistic outlook, with target prices spanning from $136 to $285, further bolster the positive trajectory of Natera's stock.